Acucela (AUCL) 5.6000 $AUCL
Acucela Received a Request to Hold a Special Meeting of Shareholders
Business Wire - Mon Feb 02, 4:37PM CST
Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, received a letter (the "Letter"
from SBI Holdings, Inc., the parent corporation of several Acucela shareholders (collectively, "SBI" , stating its demand that Acucela hold a special meeting of its shareholders for the purposes of removing Acucela's current board members, other than Dr. Ryo Kubota, and electing a slate of four directors identified in the Letter to fill the resulting vacancies. The Letter disclosed that SBI has granted Dr. Kubota an irrevocable proxy over the shares held by SBI which, together with Dr. Kubota's holdings, represent 50.28% of Acucela's total outstanding Common Shares as of the date of the Letter.
Acucela Announces That Brian O'Callaghan Will Assume the Role of CEO; Ryo Kubota, M.D., Ph.D., to Remain Chairman of the Board
Business Wire - Mon Dec 22, 9:26PM CST
Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company focused on discovering and developing novel therapeutics to treat the progression of sight-threatening ophthalmic diseases, today announced that Brian O'Callaghan, Acucela's President and Chief Operating Officer (COO), will assume the role of Chief Executive Officer (CEO), along with continuing to serve as Interim Chief Financial Officer (CFO). Ryo Kubota, M.D., Ph.D., Acucela's Founder, will retain his position as Chairman of Acucela's Board of Directors. Mr. O'Callaghan will assume the role of CEO effective January 1, 2015.
Global Retinopathy Of Prematurity Therapeutics Pipeline Review, H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
M2 - Tue Nov 11, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/tdsmfd/retinopathy_of) has announced the addition of the "Retinopathy Of Prematurity - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinopathy Of Prematurity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinopathy Of Prematurity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Insmed Incorporated - Acucela Inc. - Gene Signal International SA - EyeGene, Inc. - Biomar Microbial Technologies Drug Profiles - mecasermin rinfabate - ranibizumab - aganirsen - Small Molecule for Retinopathy Of Prematurity - emixustat hydrochloride - EG-Mirotin - IB-09A0133 - R-200 For more information visit http://www.researchandmarkets.com/research/td...nopathy_of
INSM: 17.40 (+0.69)
Global Diabetic Retinopathy Therapeutics Pipeline Report H2 2014 - Analysis of 28 Companies & 44 Drug Profiles
M2 - Mon Nov 10, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc9dhb/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kowa Company, Ltd. - Antisense Therapeutics Limited - BioDiem Ltd - Regeneron Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Paloma Pharmaceuticals, Inc. - Acucela Inc. - Gene Signal International SA - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Angstrom Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Dimerix Bioscience Pty Ltd - Resolvyx Pharmaceuticals, Inc - Charlesson LLC. - MacuCLEAR, Inc. - Stelic Institute & Co. - EyeCyte, Inc. - Vascular Pharmaceuticals, Inc. - PanOptica, Inc. - EyeGene, Inc. - Targazyme, Inc. - Aprogen, Inc. - MingSight Pharmaceuticals - Bionure Farma, S.L. - Islet Sciences, Inc. - Foresee Pharmaceuticals, LLC - Biomar Microbial Technologies Drug Profiles - aflibercept (recombinant) - ripasudil - AKB-9778 - ATL-1103 - DG-3173 - emixustat hydrochloride - aganirsen - GLY-230 - EG-Mirotin - Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - DT-23552 - RX-20001 - A-6 - P-529 - BDM-E - RTU-007 - Mesenchymal Stem Cells - PRM-167 - A-717 - MS-553 - PAN-90806 - MC-4001 - AP-202 - FP-002 - Recombinant Protein for Cancer and Diabetic Retinopathy - Cyndacel-M - VPI-2690-B - Small Molecule for Diabetic Neuropathy and Retinopathy - TZ-101 - V-1932 For more information visit http://www.researchandmarkets.com/research/sc9dhb/diabetic
ITEK: (), REGN: 402.40 (+0.66)
Acucela's Emixustat Hydrochloride, in Development for Geographic Atrophy Associated with Dry Age-Related Macular Degeneration, Subject of Podium Presentation at the American Academy of Ophthalmology 2014 Annual Meeting
Business Wire - Thu Oct 16, 6:30PM CDT
Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that results on the pharmacodynamic properties of emixustat hydrochloride in patients with geographic atrophy will be presented by Roger L. Novack, MD, PhD, Retina-Vitreous Associates Medical Group, Beverly Hills, California, during a podium session at the American Academy of Ophthalmology (AAO) 2014 Annual Meeting in Chicago, IL on Tuesday, October 21, 2014 at 10:46AM, CT. The abstract can be accessed at: http://www.aao.org/meetings/annual_meeting/program/. The presentation is entitled "Pharmacodynamic Properties of Emixustat Hydrochloride in the Treatment of Geographic Atrophy (PA089)." Emixustat, the first internally developed investigational compound by Acucela, is orally dosed, targets the visual cycle, and is in development for the treatment of GA associated with dry AMD. Dr. Novack was one of the investigators in Acucela's Phase 2a clinical study and is currently participating as an investigator in the Phase 2b/3 "SEATTLE" study.
Acucela to Present at the BioCentury NewsMakers in the Biotech Industry Conference
Business Wire - Wed Sep 17, 6:00PM CDT
Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that its Founder, Chairman and CEO, Ryo Kubota, MD, PhD, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 10:00 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York City, New York.
Acucela Appoints Biotechnology Industry Veteran and Former Pharmaceutical Executive, Brian O'Callaghan, as Its New President and Chief Operating Officer and Interim CFO; Ryo Kubota, MD, PhD, to Remain in His Role as Chairman and CEO
Business Wire - Mon Sep 08, 7:15PM CDT
Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that after a long and thoughtful strategic planning process to recruit a new President and Chief Operating Officer (COO), Acucela has appointed Brian O'Callaghan, who currently sits on Acucela's Board of Directors, to the newly created position, effective immediately. Ryo Kubota, MD, PhD, who is also Acucela's Founder, will remain as Acucela's Chairman of the Board (Chairman) and Chief Executive Officer (CEO). In a separate development, Acucela's Chief Financial Officer (CFO), David Lowrance, will be leaving the Company for family reasons. As a result of Mr. Lowrance's departure, Mr. O'Callaghan will also assume the role of Interim CFO. An active search is underway to appoint a new CFO. Mr. O'Callaghan brings to Acucela over 25 years of leadership experience in the biotechnology and pharmaceutical industries, including senior positions at Bayer, Merck, Novartis, NPS Pharmaceuticals, Pfizer, and Sangart. He will report directly into Dr. Kubota.
MRK: 58.81 (-0.07), NPSP: 45.88 (+0.03), NVS: 102.20 (-0.17)
Acucela Received a Request to Hold a Special Meeting of Shareholders
Business Wire - Mon Feb 02, 4:37PM CST
Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, received a letter (the "Letter"
from SBI Holdings, Inc., the parent corporation of several Acucela shareholders (collectively, "SBI" , stating its demand that Acucela hold a special meeting of its shareholders for the purposes of removing Acucela's current board members, other than Dr. Ryo Kubota, and electing a slate of four directors identified in the Letter to fill the resulting vacancies. The Letter disclosed that SBI has granted Dr. Kubota an irrevocable proxy over the shares held by SBI which, together with Dr. Kubota's holdings, represent 50.28% of Acucela's total outstanding Common Shares as of the date of the Letter. Acucela Announces That Brian O'Callaghan Will Assume the Role of CEO; Ryo Kubota, M.D., Ph.D., to Remain Chairman of the Board
Business Wire - Mon Dec 22, 9:26PM CST
Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company focused on discovering and developing novel therapeutics to treat the progression of sight-threatening ophthalmic diseases, today announced that Brian O'Callaghan, Acucela's President and Chief Operating Officer (COO), will assume the role of Chief Executive Officer (CEO), along with continuing to serve as Interim Chief Financial Officer (CFO). Ryo Kubota, M.D., Ph.D., Acucela's Founder, will retain his position as Chairman of Acucela's Board of Directors. Mr. O'Callaghan will assume the role of CEO effective January 1, 2015.
Global Retinopathy Of Prematurity Therapeutics Pipeline Review, H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
M2 - Tue Nov 11, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/tdsmfd/retinopathy_of) has announced the addition of the "Retinopathy Of Prematurity - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinopathy Of Prematurity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinopathy Of Prematurity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Insmed Incorporated - Acucela Inc. - Gene Signal International SA - EyeGene, Inc. - Biomar Microbial Technologies Drug Profiles - mecasermin rinfabate - ranibizumab - aganirsen - Small Molecule for Retinopathy Of Prematurity - emixustat hydrochloride - EG-Mirotin - IB-09A0133 - R-200 For more information visit http://www.researchandmarkets.com/research/td...nopathy_of
INSM: 17.40 (+0.69)
Global Diabetic Retinopathy Therapeutics Pipeline Report H2 2014 - Analysis of 28 Companies & 44 Drug Profiles
M2 - Mon Nov 10, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc9dhb/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kowa Company, Ltd. - Antisense Therapeutics Limited - BioDiem Ltd - Regeneron Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Paloma Pharmaceuticals, Inc. - Acucela Inc. - Gene Signal International SA - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Angstrom Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Dimerix Bioscience Pty Ltd - Resolvyx Pharmaceuticals, Inc - Charlesson LLC. - MacuCLEAR, Inc. - Stelic Institute & Co. - EyeCyte, Inc. - Vascular Pharmaceuticals, Inc. - PanOptica, Inc. - EyeGene, Inc. - Targazyme, Inc. - Aprogen, Inc. - MingSight Pharmaceuticals - Bionure Farma, S.L. - Islet Sciences, Inc. - Foresee Pharmaceuticals, LLC - Biomar Microbial Technologies Drug Profiles - aflibercept (recombinant) - ripasudil - AKB-9778 - ATL-1103 - DG-3173 - emixustat hydrochloride - aganirsen - GLY-230 - EG-Mirotin - Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - DT-23552 - RX-20001 - A-6 - P-529 - BDM-E - RTU-007 - Mesenchymal Stem Cells - PRM-167 - A-717 - MS-553 - PAN-90806 - MC-4001 - AP-202 - FP-002 - Recombinant Protein for Cancer and Diabetic Retinopathy - Cyndacel-M - VPI-2690-B - Small Molecule for Diabetic Neuropathy and Retinopathy - TZ-101 - V-1932 For more information visit http://www.researchandmarkets.com/research/sc9dhb/diabetic
ITEK: (), REGN: 402.40 (+0.66)
Acucela's Emixustat Hydrochloride, in Development for Geographic Atrophy Associated with Dry Age-Related Macular Degeneration, Subject of Podium Presentation at the American Academy of Ophthalmology 2014 Annual Meeting
Business Wire - Thu Oct 16, 6:30PM CDT
Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that results on the pharmacodynamic properties of emixustat hydrochloride in patients with geographic atrophy will be presented by Roger L. Novack, MD, PhD, Retina-Vitreous Associates Medical Group, Beverly Hills, California, during a podium session at the American Academy of Ophthalmology (AAO) 2014 Annual Meeting in Chicago, IL on Tuesday, October 21, 2014 at 10:46AM, CT. The abstract can be accessed at: http://www.aao.org/meetings/annual_meeting/program/. The presentation is entitled "Pharmacodynamic Properties of Emixustat Hydrochloride in the Treatment of Geographic Atrophy (PA089)." Emixustat, the first internally developed investigational compound by Acucela, is orally dosed, targets the visual cycle, and is in development for the treatment of GA associated with dry AMD. Dr. Novack was one of the investigators in Acucela's Phase 2a clinical study and is currently participating as an investigator in the Phase 2b/3 "SEATTLE" study.
Acucela to Present at the BioCentury NewsMakers in the Biotech Industry Conference
Business Wire - Wed Sep 17, 6:00PM CDT
Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that its Founder, Chairman and CEO, Ryo Kubota, MD, PhD, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 10:00 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York City, New York.
Acucela Appoints Biotechnology Industry Veteran and Former Pharmaceutical Executive, Brian O'Callaghan, as Its New President and Chief Operating Officer and Interim CFO; Ryo Kubota, MD, PhD, to Remain in His Role as Chairman and CEO
Business Wire - Mon Sep 08, 7:15PM CDT
Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that after a long and thoughtful strategic planning process to recruit a new President and Chief Operating Officer (COO), Acucela has appointed Brian O'Callaghan, who currently sits on Acucela's Board of Directors, to the newly created position, effective immediately. Ryo Kubota, MD, PhD, who is also Acucela's Founder, will remain as Acucela's Chairman of the Board (Chairman) and Chief Executive Officer (CEO). In a separate development, Acucela's Chief Financial Officer (CFO), David Lowrance, will be leaving the Company for family reasons. As a result of Mr. Lowrance's departure, Mr. O'Callaghan will also assume the role of Interim CFO. An active search is underway to appoint a new CFO. Mr. O'Callaghan brings to Acucela over 25 years of leadership experience in the biotechnology and pharmaceutical industries, including senior positions at Bayer, Merck, Novartis, NPS Pharmaceuticals, Pfizer, and Sangart. He will report directly into Dr. Kubota.
MRK: 58.81 (-0.07), NPSP: 45.88 (+0.03), NVS: 102.20 (-0.17)
